Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,383,007
  • Shares Outstanding, K 96,478
  • Annual Sales, $ 560,230 K
  • Annual Income, $ -569,180 K
  • EBIT $ -544 M
  • EBITDA $ -521 M
  • 60-Month Beta 0.16
  • Price/Sales 3.81
  • Price/Cash Flow N/A
  • Price/Book 250.60

Options Overview Details

View History
  • Implied Volatility 60.34% (-14.91%)
  • Historical Volatility 170.15%
  • IV Percentile 53%
  • IV Rank 15.17%
  • IV High 187.31% on 12/26/25
  • IV Low 37.62% on 09/11/25
  • Expected Move (DTE 11) 1.79 (7.23%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 259
  • Volume Avg (30-Day) 1,265
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 31,773
  • Open Int (30-Day) 44,400
  • Expected Range 22.92 to 26.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.22
  • Number of Estimates 10
  • High Estimate -0.71
  • Low Estimate -1.76
  • Prior Year -1.39
  • Growth Rate Est. (year over year) +12.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.00 +12.27%
on 01/20/26
25.82 -4.34%
on 02/03/26
+2.16 (+9.58%)
since 01/06/26
3-Month
18.41 +34.17%
on 12/29/25
39.89 -38.08%
on 12/08/25
-6.25 (-20.19%)
since 11/06/25
52-Week
18.41 +34.17%
on 12/29/25
46.27 -46.62%
on 02/14/25
-21.08 (-46.05%)
since 02/06/25

Most Recent Stories

More News
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

NEW ORLEANS , Feb. 6, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications...

RARE : 24.70 (+3.83%)
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023...

RARE : 24.70 (+3.83%)
Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE)

PHILADELPHIA , Feb. 6, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical...

RARE : 24.70 (+3.83%)
RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options

RARE : 24.70 (+3.83%)
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RARE

The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ: RARE ) for violations of §§10(b)...

RARE : 24.70 (+3.83%)
RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc.

SAN DIEGO , Feb. 6, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical...

RARE : 24.70 (+3.83%)
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti , LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx”...

RARE : 24.70 (+3.83%)
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ:...

RARE : 24.70 (+3.83%)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update

NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...

RARE : 24.70 (+3.83%)
Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December...

RARE : 24.70 (+3.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 26.06
2nd Resistance Point 25.47
1st Resistance Point 25.08
Last Price 24.70
1st Support Level 24.10
2nd Support Level 23.51
3rd Support Level 23.12

See More

52-Week High 46.27
Fibonacci 61.8% 35.63
Fibonacci 50% 32.34
Fibonacci 38.2% 29.05
Last Price 24.70
52-Week Low 18.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar